159 results
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
, 2023 were JPY 534.1 billion.
Takeda’s R&D engine is focused on translating science into highly innovative, life-transformative medicines that make … a critical difference to patients. Takeda supports dedicated R&D efforts across three areas: Innovative Biopharma, Plasma-Derived Therapies (“PDT
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 23
Current report (foreign)
6:01am
that will enable us to continue to deliver innovative medicines to patients and grow the company sustainably over the long term. In the near-term, we
6-K
TAK
Takeda Pharmaceutical Co
13 Nov 23
Current report (foreign)
6:05am
at Takeda. “As we strive to help patients with limited or no treatment options, developing innovative treatments in rare diseases is an inspiring challenge
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
September 30, 2023 were JPY 346.7 billion.
Takeda’s R&D engine is focused on translating science into highly innovative, life-transformative medicines … that make a critical difference to patients. Takeda supports dedicated R&D efforts across three areas: Innovative Biopharma, Plasma-Derived Therapies
6-K
TAK
Takeda Pharmaceutical Co
1 Aug 23
Current report (foreign)
6:10am
30, 2023 were JPY 162.7 billion.
Takeda’s R&D engine is focused on translating science into highly innovative, life-transformative medicines … that make a critical difference to patients. Takeda supports dedicated R&D efforts across three areas: Innovative Biopharma, Plasma-Derived Therapies (“PDT
6-K
EX-99.1
7ilz8udxd40oyh
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
9xicblq
23 Jun 23
Current report (foreign)
6:13am
6-K
0io if19pl6ucss0sm6
30 May 23
Current report (foreign)
6:20am
6-K
EX-99.1
v7fn23
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
69wi9zea 65io
30 May 23
Current report (foreign)
6:11am
6-K
hmjw q569uhr
11 May 23
Current report (foreign)
6:07am
6-K
wtxu nzseys76qja
30 Mar 23
Current report (foreign)
6:19am
6-K
9to sm45xm
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
jea8n4s
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
c3t4m
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
9t3tw52e
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
02phg0g6q7a
8 Dec 22
Current report (foreign)
6:46am
6-K
rdnz3sqll
4 Nov 22
Current report (foreign)
6:01am
6-K
6l2 wporo
14 Oct 22
Current report (foreign)
7:36am